Edward Loftus Jr., MD

A conclusion emphasizing the importance of translating clinical research into everyday practice and continuing innovation to improve patient quality of life and long-term outcomes.

Forward-looking perspectives on how predictive biomarkers, genetic profiling, and precision tools will guide individualized IBD management in the coming years.

Exploration of combination and sequencing strategies for patients with refractory or advanced disease to achieve comprehensive disease control.

Analysis of how to balance established therapies such as anti-TNFs and immunomodulators with novel agents like JAK inhibitors, S1P modulators, and IL-23 inhibitors.

Insight into how response patterns from major studies help identify optimal treatment timing and predict which patients benefit most from specific interventions.

A focused review of evidence showing that early initiation of biologic therapy leads to higher remission and healing rates compared to later-stage treatment.

Insight into how response patterns from major studies help identify optimal treatment timing and predict which patients benefit most from specific interventions.

Examination of how deeper healing correlates with improved long-term outcomes, emphasizing the translation of clinical trial findings into practical treatment adjustments.

An overview of the changing IBD treatment landscape, highlighting how deeper remission targets and emerging therapies are redefining patient care and treatment goals.

An overview of the changing IBD treatment landscape, highlighting how deeper remission targets and emerging therapies are redefining patient care and treatment goals.

Jessica Allegretti, MD, MPH, and Edward Loftus Jr., MD, review emerging agents in the later phases for the management of IBD.

Expert gastroenterologists review the unmet needs in IBD management.

Details of the head-to-head SEAVUE study of ustekinumab vs adalimumab for induction and maintenance therapy in patients with moderate to severe Crohn disease.

Edward Loftus Jr, MD, and William Sandborn, MD, review the 5-year remission data from the IM-UNITI trial for ustekinumab and post hoc analysis from the GEMINI 2 trial for vedolizumab in patients with Crohn disease.

A panel of experts share their experiences with the use of biologics for the treatment of inflammatory bowel diseases (IBDs).

Indications for surgery in treating patients for ulcerative colitis (UC) and Crohn disease.

Initial IBD therapy for a patient with low-risk disease and measuring treatment response on initial therapy.

Important patient factors to consider other than severity of disease when choosing a therapeutic agent for inflammatory bowel disease.

A panel of experts discuss the latest guidelines and how they make a treatment decision for patients with ulcerative colitis and Crohn’s disease.

Panel of gastroenterologists share their perspectives regarding the diagnostic work-up for patients who may have symptoms suggestive of IBD.

Expert opinions on the effect of the progressive, relapsing nature of inflammatory bowel disease on a patients’ quality of life.

Effect of age, gender, racial, and socioeconomic disparities on the incidence and prevalence of inflammatory bowel disease (IBD).

Expert gastroenterologists review the pathophysiology of inflammatory bowel disease (IBD) along with the associated risk factors.